Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Outcomes Among Patients Receiving Enzalutamide Plus ADT or Darolutamide Plus ADT in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

NCT07779590 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07779590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07779590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Outcomes Among Patients Receiving Enzalutamide Plus ADT or Darolutamide Plus ADT in Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Active, not recruiting
Start date
August 19, 2026
Completion date
November 15, 2026
Enrollment
4,700 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration sensitive prostate cancer (mcspc)